ID   YT
AC   CVCL_1797
SY   YT-0
DR   BTO; BTO:0005228
DR   CLO; CLO_0009718
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioSample; SAMN03473541
DR   Cell_Model_Passport; SIDM00410
DR   ChEMBL-Cells; CHEMBL3308146
DR   ChEMBL-Targets; CHEMBL2366114
DR   Cosmic; 850219
DR   Cosmic; 946358
DR   Cosmic; 991546
DR   Cosmic; 1012130
DR   Cosmic; 1524828
DR   Cosmic; 1542072
DR   Cosmic; 2390120
DR   Cosmic; 2785211
DR   Cosmic-CLP; 946358
DR   DepMap; ACH-002317
DR   DSMZ; ACC-434
DR   DSMZCellDive; ACC-434
DR   EGA; EGAS00001000978
DR   GDSC; 946358
DR   GEO; GSM236811
DR   GEO; GSM236847
DR   GEO; GSM472010
DR   GEO; GSM1670588
DR   IARC_TP53; 27711
DR   LINCS_LDP; LCL-1913
DR   PharmacoDB; YT_1688_2019
DR   PRIDE; PXD030304
DR   PubChem_Cell_line; CVCL_1797
DR   Wikidata; Q54995532
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1313126;
RX   PubMed=2578514;
RX   PubMed=3098894;
RX   PubMed=9787181;
RX   PubMed=10803505;
RX   PubMed=16408098;
RX   PubMed=16827800;
RX   PubMed=19194464;
RX   PubMed=20164919;
RX   PubMed=20454443;
RX   PubMed=21052088;
RX   PubMed=25586472;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=YT
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Doubling time: ~40-50 hours (DSMZ=ACC-434).
CC   HLA typing: A*26:01:01,31:01:02; B*48:01:01,48:01:01; C*01:02:01,08:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:01:01,01:01:01; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-434).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.12%; Native American=0.69%; East Asian, North=74.01%; East Asian, South=25.17%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from site: In situ; Pericardial effusion; UBERON=UBERON_0002409.
CC   Cell type: Natural killer cell; CL=CL_0000623.
ST   Source(s): Cosmic-CLP; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 9,11
ST   D16S539: 10,12
ST   D18S51: 14,16
ST   D19S433: 14,15
ST   D21S11: 30,32
ST   D2S1338: 19,20
ST   D3S1358: 15,17
ST   D5S818: 10,11
ST   D7S820: 11,12
ST   D8S1179: 13,16
ST   FGA: 22,23
ST   Penta D: 10,11
ST   Penta E: 15
ST   TH01: 6,7
ST   TPOX: 8
ST   vWA: 17,18,20 (DSMZ)
ST   vWA: 17,20 (Cosmic-CLP)
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 33
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1313126;
RA   Yoneda N., Tatsumi E., Kawano S., Teshigawara K., Oka T., Fukuda M.,
RA   Yamaguchi N.;
RT   "Detection of Epstein-Barr virus genome in natural-killer-like cell
RT   line, YT.";
RL   Leukemia 6:136-141(1992).
//
RX   PubMed=2578514; DOI=10.4049/jimmunol.134.3.1623;
RA   Yodoi J., Teshigawara K., Nikaido T., Fukui K., Noma T., Honjo T.,
RA   Takigawa M., Sasaki M., Minato N., Tsudo M., Uchiyama T., Maeda M.;
RT   "TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2
RT   receptor on a natural killer-like cell line (YT cells).";
RL   J. Immunol. 134:1623-1630(1985).
//
RX   PubMed=3098894; DOI=10.1084/jem.165.1.223;
RA   Teshigawara K., Wang H.-M., Kato K., Smith K.A.;
RT   "Interleukin 2 high-affinity receptor expression requires two distinct
RT   binding proteins.";
RL   J. Exp. Med. 165:223-238(1987).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x;
RA   Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.;
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.,
RA   Klinkebiel D., Christman J.K., Patel K., Cao K., Shen L., Dybkaer K.,
RA   Tsui I.F.L., Ali H., Shimizu N., Au W.Y., Lam W.L., Chan W.C.;
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20454443; DOI=10.1155/2010/904767;
RA   Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.;
RT   "Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human
RT   and other primate cell lines.";
RL   J. Biomed. Biotechnol. 2010:904767.1-904767.23(2010).
//
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.Y., Srivastava G.,
RA   Greiner T.C., Kucuk C., Deffenbacher K., Vose J.M., Smith L., Au W.Y.,
RA   Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H.,
RA   Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.C.;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RL   Leukemia 25:348-358(2011).
//
RX   PubMed=25586472; DOI=10.1038/ncomms7025;
RA   Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M.,
RA   Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A.,
RA   Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A.,
RA   Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K.,
RA   de Leval L., McKeithan T.W., Chan W.C.;
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//